Electra Therapeutics, Inc. (ETRA): who owns it and who trades it
As of Nov 16, 2026, ETRA insiders reported 18 purchases worth $24.3M in the last 12 months. The largest buyer was Carl L Gordon (Director), with $20M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Electra Therapeutics
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, ETRA insiders reported $24.3M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 20,700 | $8.45 | $175K | Form 4 |
| Nov 10, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 2,000 | $8.45 | $16.9K | Form 4 |
| Nov 9, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 4,000 | $8.24 | $33K | Form 4 |
| Nov 9, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 16,000 | $8.24 | $132K | Form 4 |
| Nov 6, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 9,816 | $7.85 | $77.1K | Form 4 |
| Nov 6, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 39,600 | $7.85 | $311K | Form 4 |
| Nov 5, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 30,891 | $7.31 | $226K | Form 4 |
| Nov 5, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 125,200 | $7.31 | $915K | Form 4 |
| Nov 4, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 9,267 | $7.78 | $72.1K | Form 4 |
| Nov 4, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 37,100 | $7.78 | $289K | Form 4 |
| Nov 4, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 5,000 | $7.07 | $35.4K | Form 4 |
| Nov 4, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 20,000 | $7.07 | $141K | Form 4 |
| Nov 3, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 24,313 | $7.84 | $191K | Form 4 |
| Nov 3, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 97,800 | $7.84 | $767K | Form 4 |
| Nov 3, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 24,400 | $7.88 | $192K | Form 4 |
| Nov 3, 2026 | Orbimed Advisors Llc +2 | Director | Purchase | 98,600 | $7.88 | $777K | Form 4 |
| Sep 21, 2026 | Carl L Gordon | Director | Purchase | 333,333 | $15.00 | $5M | Form 4 |
| Sep 21, 2026 | Carl L Gordon | Director | Purchase | 1.00M | $15.00 | $15M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Carl L Gordon | Director, 10% owner | $20M | – | Sep 21, 2026 |
| Orbimed Advisors Llc | Director, 10% owner | $4.3M | – | Nov 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ETRA short interest
484,020 ETRA shares are sold short. Over the last 3 reports the number of shares short went down 31%.
As of Oct 30, 2026, 484,020 ETRA shares were sold short, up 18.2% from the report before. At the average daily volume of 285,287 shares, buying them all back would take about 1.7 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 484,020 | – | +18% | 285,287 | 1.7 |
| Oct 15, 2026 | 409,380 | – | -42% | 516,107 | 1.0 |
| Sep 30, 2026 | 702,266 | – | – | 909,492 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Electra Therapeutics company events
Electra Therapeutics filed 1 report on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 21, 2026.
- Sep 21, 2026AnnouncementThe Company closed its IPO of an aggregate of 23,333,334 shares of common stock at a price to the public of $15.00 per share. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold ETRA
5 of the 50 well-known investors we track reported holding ETRA in their latest 13F filing. The largest position is Israel Englander's, worth $4.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 368,373 | $4.1M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 145,584 | $1.6M | 0.0% | New |
| George Soros · Soros Fund Management | Q3 2026 | 75,000 | $844K | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 47,005 | $529K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 13,354 | $150K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ETRA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G | 5.4% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G | 5.4% |
| Oct 29, 2026 | Westlake BioPartners Fund I, L.P. | 13G | 5.6% |
| Oct 29, 2026 | Westlake BioPartners Fund I, L.P. | 13G | 5.6% |
Questions about Electra Therapeutics, Inc. (ETRA) stock
Are ETRA insiders buying or selling?
In the last 12 months, ETRA insiders reported 18 open-market purchases worth $24.3M and no sales. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in ETRA?
As of Oct 30, 2026, 484,020 ETRA shares were sold short, up 18.2% from the report before. At the average daily volume of 285,287 shares, buying them all back would take about 1.7 trading days (days to cover). See the history.
Which famous investors hold ETRA?
5 of the 50 well-known investors we track reported ETRA in their latest 13F filing, including Israel Englander, Ken Griffin, George Soros. The largest position is worth $4.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.